News
Orionis Biosciences has announced a multi-year partnership with Roche’s Genentech, focusing on the discovery and development of small-molecule monovalent glue medicines for difficult targets in ...
Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the molecular glue biotech.
Genentech signed onto a $47 million partnership with biotech Orionis Biosciences to focus on discovering novel small molecule therapies across various therapeutic areas, including cancer and ...
Orionis Biosciences, a privately held company, announced a second multi-year collaboration with Genentech, a member of the Roche Group (OTCQX:RHHBY). The goal of this partnership is to discover ...
Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...
Orionis Biosciences, a privately held life sciences company with an integrated drug discovery and chemical biology platform, announced today a multi-y ...
Orionis Biosciences Announces Strategic Partnership with Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer Orionis to receive $105 million upfront, as well as future ...
The multiyear licensing pact with Orionis Biosciences will use the Boston-based biotech’s Allo-Glue platform to discover and optimize molecular glues for targets designated by Genentech.
Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results